Unknown

Dataset Information

0

Biofilm Formation of Clostridioides difficile, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI.


ABSTRACT: Clostridioides difficile is considered a nosocomial pathogen that flares up in patients exposed to antibiotic treatment. However, four out of ten patients diagnosed with C. difficile infection (CDI) acquired the infection from non-hospitalized individuals, many of whom have not been treated with antibiotics. Treatment of recurrent CDI (rCDI) with antibiotics, especially vancomycin (VAN) and metronidazole (MNZ), increases the risk of experiencing a relapse by as much as 70%. Fidaxomicin, on the other hand, proved more effective than VAN and MNZ by preventing the initial transcription of RNA toxin genes. Alternative forms of treatment include quorum quenching (QQ) that blocks toxin synthesis, binding of small anion molecules such as tolevamer to toxins, monoclonal antibodies, such as bezlotoxumab and actoxumab, bacteriophage therapy, probiotics, and fecal microbial transplants (FMTs). This review summarizes factors that affect the colonization of C. difficile and the pathogenicity of toxins TcdA and TcdB. The different approaches experimented with in the destruction of C. difficile and treatment of CDI are evaluated.

SUBMITTER: Dicks LMT 

PROVIDER: S-EPMC10534356 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Biofilm Formation of <i>Clostridioides difficile</i>, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI.

Dicks Leon M T LMT  

Microorganisms 20230826 9


<i>Clostridioides difficile</i> is considered a nosocomial pathogen that flares up in patients exposed to antibiotic treatment. However, four out of ten patients diagnosed with <i>C. difficile</i> infection (CDI) acquired the infection from non-hospitalized individuals, many of whom have not been treated with antibiotics. Treatment of recurrent CDI (rCDI) with antibiotics, especially vancomycin (VAN) and metronidazole (MNZ), increases the risk of experiencing a relapse by as much as 70%. Fidaxom  ...[more]

Similar Datasets

2019-04-05 | GSE103952 | GEO
2023-05-24 | GSE223108 | GEO
2021-01-31 | GSE139354 | GEO
| S-EPMC10169396 | biostudies-literature
2021-05-04 | GSE165116 | GEO
| S-EPMC6941533 | biostudies-literature
| S-EPMC8371447 | biostudies-literature
| S-EPMC8630010 | biostudies-literature
| S-EPMC9137654 | biostudies-literature
| S-EPMC10166488 | biostudies-literature